Search Result

Pathways Recommended:	PROTAC

Results for "

PROTAC FLT-3 degrader

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FLT3 (17) Ligands for Target Protein for PROTAC (4) AAK1 (2) Akt (2) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (6) Aurora Kinase (1) c-Fms (1) c-Kit (1) c-Myc (1) CaMK (1) CDK (6) Checkpoint Kinase (Chk) (2) Cyclin G-associated Kinase (GAK) (1) E3 Ligase Ligand-Linker Conjugates (2) Enolase (1) Epigenetic Reader Domain (2) ERK (3) Ferroptosis (1) FGFR (1) HSP (1) IKZF Family (1) IRAK (1) JAK (2) Ligands for E3 Ligase (1) LIM Kinase (LIMK) (2) MEK (1) Molecular Glues (1) NF-κB (1) PDGFR (1) PROTACs (18) Salt-inducible Kinase (SIK) (2) SnRK (1) STAT (3) Target Protein Ligand-Linker Conjugates (2) ULK (1) VEGFR (1) Wee1 (1)
By Research Areas:	Cancer (24) Inflammation/Immunology (2) Metabolic Disease (2) Neurological Disease (1)

By Targets:

FLT3 (17)

Ligands for Target Protein for PROTAC (4)

AAK1 (2)

Akt (2)

Anaplastic lymphoma kinase (ALK) (1)

Apoptosis (6)

Aurora Kinase (1)

c-Fms (1)

c-Kit (1)

c-Myc (1)

CaMK (1)

CDK (6)

Checkpoint Kinase (Chk) (2)

Cyclin G-associated Kinase (GAK) (1)

E3 Ligase Ligand-Linker Conjugates (2)

Enolase (1)

Epigenetic Reader Domain (2)

ERK (3)

Ferroptosis (1)

FGFR (1)

HSP (1)

IKZF Family (1)

IRAK (1)

JAK (2)

Ligands for E3 Ligase (1)

LIM Kinase (LIMK) (2)

MEK (1)

Molecular Glues (1)

NF-κB (1)

PDGFR (1)

PROTACs (18)

Salt-inducible Kinase (SIK) (2)

SnRK (1)

STAT (3)

Target Protein Ligand-Linker Conjugates (2)

ULK (1)

VEGFR (1)

Wee1 (1)

By Research Areas:

Cancer (24)

Inflammation/Immunology (2)

Metabolic Disease (2)

Neurological Disease (1)

Targets Recommended: FLT3 PROTAC-Linker Conjugates for PAC PROTAC Linkers Ligands for Target Protein for PROTAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-130665

TL12-186 1 Publications Verification	PROTACs CDK	Cancer
TL12-186 is a Cereblon-dependent multi-kinase *PROTAC* degrader. Multi-kinases include CDK, BTK, *FLT3, Aurora kinases, TEC, ULK, ITK, et al. TL12-186 inhibits CDK2/cyclin A* (IC₅₀=73 nM) and CDK9/cyclin T1 (IC₅₀=55 nM) .

HY-114323

PROTAC FLT-3 degrader 1	PROTACs FLT3 Apoptosis STAT MEK ERK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
PROTAC FLT-3 degrader 1 is an effective and selective **FLT-3 PROTAC** degrader with an IC₅₀ of 0.6 nM. PROTAC FLT-3 degrader 1 inhibits both FLT-3 and FLT-3 ITD mutants. PROTAC FLT-3 degrader 1 has the activity of anti-proliferation and induction of apoptosis, which can be used in the study of tumor .

HY-W039233

Lenalidomide-F	Ligands for E3 Ligase	Cancer
Lenalidomide-F is a E3 ligase ligand for LWY713. LWY713 is a PROTAC-class FLT3 degrader (DC₅₀ = 0.64 nM), which selectively induces FLT3 degradation via cereblon and proteasome-dependent pathways .

HY-175040

PROTAC FLT-3 degrader 5	PROTACs Molecular Glues FLT3 IKZF Family	Cancer
PROTAC FLT-3 degrader 5 is a *FLT3* *PROTAC* degrader (DC₅₀ = 1.2 nM). PROTAC FLT-3 degrader 5 functions as a molecular glue to degrade cereblon substrates GSPT1 and IKZF1/3. PROTAC FLT-3 degrader 5 exhibits antiproliferative activity against drug-resistant acute myeloid leukemia (AML) cells and is potentially useful in AML research. (Pink: FLT3/GSPT1/IKZF1/3 ligand: (HY-169374); Blue: Thalidomide: (HY-14658); Black: linker; Thalidomide + linker: (HY-W1123823)) .

HY-148062

RSS0680	PROTACs CDK AAK1 Cyclin G-associated Kinase (GAK) Salt-inducible Kinase (SIK) LIM Kinase (LIMK) Wee1 SnRK	Others
RSS0680 is a small noncoding RNA (sRNA) targeting the mRNA ribosome binding site (RBS) and a PROTAC with protein kinase degradation activity (Pink: FLT3-IN-17 (HY-148070); Black: Linker (HY-W041970); Blue: E3 ligase Ligand (HY-112078)). RSS0680 competitively binds to RBS through the conserved CCUCCUCCC anti-Shine-Dalgarno (aSD) sequence and inhibits the translation initiation of target genes. RSS0680 can interact with the DUF1127 protein CcaF1, regulate its own stability and participate in bacterial oxidative stress defense, enhancing the host's resistance to heat shock and oxidative damage by affecting pathways such as C1 metabolism and pyruvate dehydrogenase complex. RSS0680 degrades AAK1, CDK1, CDK16, CDK2, CDK4, CDK6, EIF2AK4, GAK, LATSl, LIMK2, MAPK6, MAPKAPK5, MARK2, MARK4, MKNK2, NEK9, RPS6KB1, SIK2, SNRK, STK17A, STK17B, STK35, and WEEl. RSS0680 can be used to study diseases or disorders mediated by aberrant kinase activity and regulatory mechanisms of noncoding RNAs in α-proteobacteria[1][2].

HY-158325

PROTAC FLT-3 degrader 4	PROTACs FLT3 Apoptosis	Cancer
PROTAC FLT-3 degrader 4 is an orally active CRBN-based *FLT3-PROTAC* degrader that potently induces FLT3-ITD degradation through the ubiquitin-proteasome system. PROTAC FLT-3 degrader 4 shows highly selective to FLT3-ITD mutant acute myeloid leukemia (AML) cells. (Blue: CRBN ligand, Black: linker; Pink: FLT3 inhibitor) .

HY-179094

PSP-0119	PROTACs IRAK NF-κB Enolase	Inflammation/Immunology Cancer
PSP-0119 is a highly efficient and effective *PROTAC* degrader targeting IRAK4 (IC₅₀ = 2.83 nM). PSP-0119 can inhibit IRAK4 kinase activity, NF-κβ activity, and IL-1β-induced IRAK4 phosphorylation. PSP-0119 degrades IRAK4 in FLT3-mutant AML cell lines, sparing FLT3-wild-type AML cells, FLT3-wild-type samples, and normal bone marrow. PSP-0119 downregulates alpha-enolase (eNOS) of MOLM-13 cells. PSP-0119 can be used for the study of Acute Myeloid Leukemia (AML) .

HY-148521

PROTAC FLT3/CDK9 degrader-1	CDK FLT3 PROTACs Apoptosis	Cancer
PROTAC FLT3/CDK9 degrader-1 is a potent *FLT3* and CDK9 dual PROTAC degrader. PROTAC FLT3/CDK9 degrader-1 induces apoptosis and effective degradation of target proteins FLT3 and CDK9. PROTAC FLT3/CDK9 degrader-1 has the potential for the research of FLT3-ITD mutated AML .

HY-148063

DB0614	PROTACs AAK1 Aurora Kinase CaMK CDK Ferroptosis Salt-inducible Kinase (SIK) LIM Kinase (LIMK) ULK	Metabolic Disease
DB0614 is a *PROTAC* based on Cereblon ligand, which is a selective and potent targeted protein degrader of NEK9 inhibitor. DB0614 can degrade ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2 and ULK1. DB0614 can be used for research of disease or disorder mediated by aberrant kinase activity .(Blue: Thalidomide-4-OH (HY-103596), Black: linker, Pink: FLT3-IN-17 (HY-148070))

HY-178858

PROTAC FLT3/CHK1 Degrader-1	PROTACs FLT3 Checkpoint Kinase (Chk) STAT ERK c-Myc Akt	Cancer
PROTAC FLT3/CHK1 Degrader-1 is a PROTAC *FLT3/CHK1* degrader, with DC₅₀ values of 5.88 nM (FLT3) and 4.17 nM (CHK1), respectively. PROTAC FLT3/CHK1 Degrader-1 can inhibit the phosphorylation of *FLT3* downstream signaling effectors STAT5 (Tyr694), AKT (Ser473), and ERK (Tyr204), downregulate the protein level of c-Myc and maintain the expression of p53 protein. PROTAC FLT3/CHK1 Degrader-1 induces apoptosis in MV-4-11 cells. PROTAC FLT3/CHK1 Degrader-1 shows significant anti-tumor efficacy in mice bearing MV-4-11 subcutaneous xenografts. PROTAC FLT3/CHK1 Degrader-1 can be used for the study of acute myeloid leukemia (AML). (Pink: FLT3/CHK1 ligand (HY-178869 ), Blue: CRBN Ligand (HY-W093272), Black: Linker, E3 ligase ligand-linker conjugate (HY-W998238)) .

HY-161280

PROTAC FLT-3 degrader 3	PROTACs FLT3	Cancer
PROTAC FLT-3 degrader 3 (compound 35) is a *PROTACs* degrader of FLT. PROTAC FLT-3 degrader 3 has antiproliferative activity, with IC₅₀ of 7.55 nM in MV4-11 cells .

HY-161708

PROTAC FLT3/CDKs degrader-1	PROTACs CDK FLT3	Cancer
PROTAC FLT3/CDKs degrader-1 (Compound C3) is a degrader for cyclin-dependent kinases (DC₅₀ is 18.73 nM for CDK2) and the FMS-like tyrosine kinase 3 (FLT3). PROTAC FLT3/CDKs degrader-1 induces differentation of HL-60 (72.77% differentation at 6.25 nM), inhibits proliferation of AML cells, with IC₅₀s of 2.9-37 nM. PROTAC FLT3/CDKs degrader-1 is potential for ameliorating acute myeloid leukemia. (Pink: ligand for target protein FLT3/CDKs ligand-1 (HY-161709); Black: linker (HY-W012935); Black: ligand for E3 ligase Thalidomide 5-fluoride (HY-W087383))

HY-131230

Desmorpholinyl Quizartinib-PEG2-COOH	Target Protein Ligand-Linker Conjugates	Cancer
Desmorpholinyl Quizartinib-PEG2-COOH incorporates a ligand for FLT-3, and a PEG-based PROTAC linker. Desmorpholinyl Quizartinib-PEG2-COOH can be used in the synthesis of PROTAC FLT-3 degrader 1 (HY-114323). PROTAC FLT-3 degrader 1 is a PROTAC FLT-3 internal tandem duplication (ITD) degrader with an IC₅₀ 0.6 nM .

HY-175610

PROTAC FLT3/JAK2/BRD4 Degrader-1	PROTACs FLT3 JAK Epigenetic Reader Domain	Cancer
PROTAC FLT3/JAK2/BRD4 Degrader-1 is a PROTAC degrader that target *FLT3, JAK2, and BRD4* with DC₅₀ values of 5.23, 0.678, and 1.17 nM, respectively. PROTAC FLT3/JAK2/BRD4 Degrader-1 exhibits potent antiproliferative activity against MV4;11 cells (IC₅₀ = 0.79 nM) and *FLT3* mutant-transformed Ba/F3 cells. PROTAC FLT3/JAK2/BRD4 Degrader-1 induces apoptosis in MV4;11 cells. PROTAC FLT3/JAK2/BRD4 Degrader-1 demonstrates significant anti-tumor efficacy in the MV4;11 xenograft model established in NOD SCID mice. PROTAC FLT3/JAK2/BRD4 Degrader-1 can be used for the study of acute myeloid leukemia (AML). (Pink: FLT3/JAK2/BRD4 ligand (HY-175611), Blue: CRBN Ligand (HY-W087383), Black: Linker, E3 ligase ligand-linker conjugate (HY-W897939)) .

HY-143286A

PF15 TFA	PROTACs FLT3	Cancer
PF15 TFA is a *PROTAC* connected by ligands for *FLT3* kinase and CRBN. PF15 TFA is a high selective FLT3-ITD degrader，with a DC50 of 76.7 nM. PF15 TFA significantly inhibits the proliferation of FLT3-ITD-positive cells，can down-regulate the phosphorylation of FLT3 and STAT5. PF15 TFA also inhibits tumor growth in mouse models and can be used in study of leukemia .

HY-157213

LWY713	Apoptosis PROTACs FLT3	Cancer
LWY713 is a PROTAC-class FLT3 degrader (DC₅₀=0.64 nM), which selectively induces *FLT3* degradation via cereblon and proteasome-dependent pathways. LWY713 inhibits cell proliferation and induces G0/G1 phase arrest and apoptosis in MV4-11 cells. LWY713 shows effective in vivo antitumor activity in MV4-11 xenograft models . LWY713 consists of a target protein ligand (red part) Gilteritinib (HY-12432), an E3 ubiquitin ligase ligand (blue part) Lenalidomide-F (HY-W039233), and a PROTAC linker (black part) Glycolic acid (HY-W015967). E3 ubiquitin ligase and linker can form Lenalidomide-Glycolic acid (HY-169373); the active control for the target protein ligand is Naproxen Gilteritinib (HY-169374).

HY-178869

FLT3/CHK1 ligand-1	Ligands for Target Protein for PROTAC FLT3 Checkpoint Kinase (Chk)	Cancer
FLT3/CHK1 ligand-1 is a PROTAC target protein ligand that can be used for synthesis of PROTACs, such as PROTAC FLT3/CHK1 Degrader-1 (HY-178858). PROTAC FLT3/CHK1 Degrader-1 is a potent **FLT3/CHK1 PROTAC** degrader with anti-tumor activity .

HY-W998238

Thalidomide-5-F-6-azetidin-MeOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-5-F-6-azetidin-MeOH is a synthesized E3 ligase ligand-linker conjugate that can be used for synthesis of PROTAC FLT3/CHK1 Degrader-1 (HY-178858). PROTAC FLT3/CHK1 Degrader-1 is a potent *FLT3/CHK1* degrader with anti-tumor activity .

HY-170769

FLT3 Ligand-Linker Conjugate 1	Target Protein Ligand-Linker Conjugates FLT3	Cancer
FLT3 Ligand-Linker Conjugate 1 (compound 7) contains the *FLT3* ligand and a PROTAC linker, which can recruit the E3 ligase VHL. FLT3 Ligand-Linker Conjugate 1 can be used to synthesize the PROTAC RSS0680 (HY-148062). PROTAC RSS0680 is a bifunctional compound that targets protein degradation of kinases .

HY-143286

PF15	PROTACs FLT3	Cancer
PF15 is a PROTAC connected by ligands for FLT3 kinase and CRBN. PF15 is a high selective *FLT3-ITD* degrader, with a DC₅₀ of 76.7 nM. PF15 significantly inhibits the proliferation of *FLT3-ITD*-positive cells, can down-regulate the phosphorylation of *FLT3* and STAT5. PF15 also inhibits tumor growth in mouse models and can be used in study of leukemia .

HY-168702

FLT3 ligand-2	Ligands for Target Protein for PROTAC	Cancer
FLT3 ligand-2 is a Ligand for Target Protein for PROTAC. FLT3 ligand-2 can be used to synthesize PROTAC FLT-3 degrader 1 (HY-114323) .

HY-175273

MA191	PROTACs FLT3 HSP ERK STAT Akt Apoptosis	Cancer
MA191 is a *FLT3* PROTAC degrader. MA191 abrogates *FLT3* inhibitor resistance from rebound activation of mitogen-activated kinases. MA191 mediates rapid *FLT3*-ITD degradation through a mechanism requiring VHL, neddylation, and BIM. MA191 reduces *FLT3*-ITD levels before inducing apoptosis. MA191 halts AML cell proliferation in Danio rerio. MA191 can be used for the study of acute myeloid leukemia (AML) (Pink: FLT3 ligand: (HY-175311), Blue: E3 ligase CRBN Ligand (HY-112078), Black: Linker, E3 ligase ligand-linker conjugate (HY-175312)) .

HY-139996

Pomalidomide-C5-Dovitinib	PROTACs Apoptosis FLT3 c-Kit FGFR VEGFR PDGFR c-Fms	Cancer
Pomalidomide-C5-Dovitinib (compound 2) is a PROTAC containing Pomalidomide, Dovitinib and connected with CRBN. Pomalidomide-C5-Dovitinib shows enhanced antiproliferative effects against FLT3-ITD+ AML cells. Pomalidomide-C5-Dovitinib induces the degradation of the FLT3-ITD and KIT proteins in a ubiquitin-proteasome-dependent manner and completely blocks their downstream signaling pathway. Pomalidomide-C5-Dovitinib has the potential for the research of FLT3-ITD ⁺ acute myeloid leukemia .

HY-161709

FLT3/CDKs ligand-1	Ligands for Target Protein for PROTAC FLT3 CDK	Cancer
FLT3/CDKs ligand-1 (Compound 14) is a ligand for target protein, which promotes the degradation of cyclin-dependent kinase (CDK) and the FMS-like tyrosine kinase 3 (FLT3), inhibits FLT3/CDK related proliferations and survivals of leukemia cells. LT3/CDKs ligand-1 can be used for synthesis of PROTAC FLT3/CDKs degrader-1 (HY-161708) .

HY-175611

FLT3/JAK2/BRD4 ligand-1	Ligands for Target Protein for PROTAC FLT3 JAK Epigenetic Reader Domain	Cancer
FLT3/JAK2/BRD4 ligand-1 is a *FLT3/JAK2/BRD4* ligand. FLT3/JAK2/BRD4 ligand-1 can be used for synthesis PROTAC FLT3/JAK2/BRD4 Degrader-1(HY-175610) .

HY-169373

Lenalidomide-Glycolic acid	E3 Ligase Ligand-Linker Conjugates	Others
Lenalidomide-Glycolic acid is a E3 Ligase Ligand-Linker Conjugate for PROTAC-class FLT3 degrader LWY713 (HY-157213) .

HY-180972

PROTAC EML4-ALK Degrader-2	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
PROTAC EML4-ALK Degrader-2 is an EML4-ALK *PROTAC* degrader. PROTAC EML4-ALK Degrader-2 shows potent selective inhibitory activity to ALK with an IC₅₀ of 1.6 nM. PROTAC EML4-ALK exhibits selectivity over IGF1R, INSR, FLT3, and FGFR2. PROTAC EML4-ALK Degrader-2 shows anti-cancer activities both in vitro and vivo. PROTAC EML4-ALK Degrader-2 can be used for non-small cell lung cancer (NSLC), liver lung and cervical cancer research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

PROTAC FLT-3 degrader

Inhibitors & Agonists